| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Pathways |
Authors' Affiliations: 1 Massachusetts General Hospital Cancer Center; 2 Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute; and 3 Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Requests for reprints: Pasi A. Jänne, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, D820A, 44 Binney Street, Boston, MA 02115. Phone: 617-632-6036; Fax: 617-582-7683; E-mail: pjanne{at}partners.org.
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung cancer patients whose tumors harbor somatic mutations in EGFR. All patients, however, ultimately develop resistance to these agents. Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers. Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene. These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies. Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non–small cell lung cancer patients.
This article has been cited by other articles:
|
|
 |
|
  S. A. Cannistra Phase II Trials in Journal of Clinical Oncology J. Clin. Oncol., July 1, 2009; 27(19): 3073 - 3076. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Yamada and K.-W. Lee Perspectives in mammalian IGFBP-3 biology: local vs. systemic action Am J Physiol Cell Physiol, May 1, 2009; 296(5): C954 - C976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sos, M. Koker, B. A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, et al. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR Cancer Res., April 15, 2009; 69(8): 3256 - 3261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, L. Wang, P. A. Janne, and G. M. Makrigiorgos Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR Clin. Chem., April 1, 2009; 55(4): 748 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Eder, G. F. Vande Woude, S. A. Boerner, and P. M. LoRusso Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2207 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, and P. M. Harari Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells Clin. Cancer Res., March 1, 2009; 15(5): 1585 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Ann. Onc., February 1, 2009; 20(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Reid Cancer Risk Assessment and Cancer Prevention: Promises and Challenges Cancer Prevention Research, September 1, 2008; 1(4): 229 - 232. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
